Clinical implication and prognostic significance of standardised uptake value of primary non-small cell lung cancer on positron emission tomography: analysis of 176 cases

European Journal of Cardio-thoracic Surgery

Volumn 34, Issue 4, 2008, Pages 892-897

  Al Sarraf, Nael ^a,b   Gately, Kathy ^a   Lucey, Julie ^c   Aziz, Rashid ^a   Doddakula, Kishore ^a   Wilson, Lorraine ^c   McGovern, Eillish ^a   Young, Vincent ^a  

^a ST JAMES S HOSPITAL   (Ireland)

^b Chest Diseases Hospital Kuwait   (Kuwait)

^c Blackrock Clinic Ireland   (Ireland)

Author keywords

Non small cell lung cancer; Positron emission tomography; Standardized uptake value; Survival

Indexed keywords

ADJUVANT CHEMOTHERAPY; ARTICLE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CORRELATION ANALYSIS; HISTOLOGY; HUMAN; LOBECTOMY; LOG RANK TEST; LUNG NON SMALL CELL CANCER; LYMPH NODE; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BLOOD VESSELS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PLEURA; POSITRON-EMISSION TOMOGRAPHY; PREOPERATIVE CARE; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 52949100615     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcts.2008.07.023     Document Type: Article

References (21)

1. Reed C.E., Harpole D.H., Posther K.E., Woolson S.L., Downey R.J., Meyers B.F., Heelan R.T., MacApinlac H.A., Jung S.H., Silvestri G.A., Siegel B.A., and Rusch V.W. Results of the American college of surgeons oncology group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer. J Thorac Cardiovasc Surg 126 6 (2003) 1943-1951
2. Woodard H.Q., Bigler R.E., and Freed B. Expression of tissue isotope distribution. J Nucl Med 16 10 (1975) 958-959
3. Mountain C.F. Revisions in the international system for staging lung cancer. Chest 111 (1997) 1710-1717
4. Al-Sarraf N., Aziz R., Doddakula K., Gately K., Wilson L., McGovern E., and Young V. Factors causing inaccurate staging of mediastinal nodal involvement in non-small cell lung cancer patients staged by positron emission tomography. Interact Cardiovasc Thorac Surg 6 3 (2007) 350-353
5. Al-Sarraf N., Gately K., Lucey J., Wilson L., McGovern E., and Young V. Lymph node staging by means of positron emission tomography is less accurate in non-small cell lung cancer patients with enlarged lymph nodes: analysis of 1145 lymph nodes. Lung Cancer 60 1 (2008) 62-68
6. Al-Sarraf N., Aziz R., Gately K., Lucey J., Wilson L., McGovern E., and Young V. Pattern and predictors of occult mediastinal lymph node involvement in non-small cell lung cancer patients with negative mediastinal uptake on positron emission tomography. Eur J Cardiothorac Surg 33 1 (2008) 104-109
7. Depierre A., Milleron B., Moro-Sibilot D., Chevret S., Quoix E., Lebeau B., Braun D., Breton J.L., Lemarie E., Gouva S., Paillot N., Brechot J.M., Janicot H., Lebas F.X., Terrioux P., Clavier J., Foucher P., Monchatre M., Coetmeur D., Level M.C., Leclerc P., Blanchon F., Rodier J.M., Thiberville L., Villeneuve A., Westeel V., Chastang C., and French thoracic cooperative group. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 20 (2002) 247-253
8. Van Baardwijk A., Dooms C., Van Suylen R.J., Verbeken E., Hochstenbag M., Dehing-Oberije C., Rupa D., Pastorekova S., Stroobants S., Buell U., Lambin P., Vansteenkiste J., and De Ruysscher D. The maximum uptake of 18F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1α and GLUT-1 in non-small cell lung cancer. Eur J Cancer 43 (2007) 1392-1398
9. Vesselle H., Freeman J.D., Wiens L., Stern J., Nguyen H.Q., Hawes S.E., Bastian P., Salskov A., Vallières E., and Wood D.E. Fluorodeoxyglucose uptake of primary non-small cell lung cancer at positron emission tomography: new contrary data on prognostic role. Clin Cancer Res 13 11 (2007) 3255-3263
10. Cerfolio R.J., Bryant A.S., Ohja B., and Bartolucci A.A. The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. J Thorac Cardiovasc Surg 130 (2005) 151-159
11. Downey R.J., Akhurst T., Gonen M., Vincent A., Bains M.S., Larson S., and Rusch V. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol 22 (2004) 3255-3260
12. Sasaki R., Komaki R., and Macapinlac H. SUV by FDG-PET predicts outcomes of NSCLC. Int J Radiat Oncol Biol Phys 57 Suppl. 2 (2003) S166
13. Jeong H.J., Min J.J., Park J.M., Chung J.K., Kim B.T., Jeong J.M., Lee D.S., Lee M.C., Han S.K., and Shim Y.S. Determination of the prognostic value of fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer. Nucl Med Commun 23 (2002) 865-870
14. Higashi K., Ueda Y., and Arisaka Y. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med 43 (2002) 39-45
15. Dhital K., Saunders C.A.B., Seed P.T., O'Doherty M.J., and Dussek J. 18F-Fluorodeoxyglucose positron emission tomography and its prognostic value in lung cancer. Eur J Cardiothorac Surg 18 (2000) 425-428
16. Vansteenkiste J.F., Stroobants S.G., Dupont P.J., De Leyn P.R., Verbeken E.K., Deneffe G.J., Mortelmans L.A., Demedts M.G., and Leuven Lung Cancer Group. Prognostic importance of the standardized uptake value on (18) F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. J Clin Oncol 10 (1999) 3201-3206
17. Sugawara Y., Quint L.E., Iannettoni M.D., Orringer M.B., Russo J.E., Recker B.E., Saran P.A., and Wahl R.L. Does the FDG uptake of primary non-small cell lung cancer predict prognosis? A work in progress. Clin Positron Imag 2 2 (1999) 111-118
18. Ahuja V., Coleman R.E., Herndon J., and Patz Jr. E.F. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with non small cell lung carcinoma. Cancer 83 (1998) 918-924
19. Ito T., Noguchi Y., Saton S., Hayashi H., Inayama Y., and Kitamura H. Expression of facilitative glucose transporter isoforms in lung carcinomas: its relation to histological type, differentiation grade, and tumour stage. Mod Pathol 11 (1998) 437-443
20. Suzuki K., Nagai K., Yoshida J., Nishimura M., Takahashi K., Yokose T., and Nishiwaki Y. Conventional clinicopathologic prognostic factors in surgically non-small cell lung carcinoma: a comparison of prognostic factors for each pathologic TNM stage based on multivariate analyses. Cancer 86 (1999) 1976-1984
21. Kessler R., Gasser B., Massard G., Roeslin N., Meyer P., Wihlm J.M., and Morand G. Blood vessel invasion is a major prognostic factor in resected non-small cell lung cancer. Ann Thorac Surg 62 5 (1996) 1489-1493